European Medicines Agency Accepts Valneva's Chikungunya Vaccine Marketing Authorization Application For Accelerated Assessment
Portfolio Pulse from Benzinga Newsdesk
Valneva SE announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application for its chikungunya vaccine candidate VLA1553 for scientific assessment. The application was previously granted accelerated assessment by EMA's CHMP due to the vaccine's potential public health impact and therapeutic innovation.
November 27, 2023 | 7:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Valneva SE's chikungunya vaccine candidate VLA1553 has passed EMA's technical validation, moving closer to potential market authorization in Europe.
The validation by the EMA is a significant regulatory milestone for Valneva, indicating that the vaccine candidate has met necessary requirements for a scientific assessment. This news is likely to be viewed positively by investors as it suggests progress towards potential market authorization, which could lead to future revenue streams for the company.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100